二次性副甲状腺機能亢進症治療の世界市場-2023年～2030年

概要

世界の二次性副甲状腺機能亢進症治療市場は、2022年に43億米ドルに達し、2023-2030年の予測期間中にCAGR 9.2％で成長し、2030年には85億米ドルに達すると予測されています。遺伝学やバイオマーカー研究の進歩による個別化医療へのシフトといった動向が、標的治療市場の発展を可能にし、世界の二次性副甲状腺機能亢進症治療市場を独占すると予想されます。

世界の二次性副甲状腺機能亢進症治療市場は近年大きく成長しており、今後も上昇傾向が続くと予測されます。市場は変革期を迎えており、カルシメティクスなどの新しい治療法の出現など、いくつかの重要な動向の影響を受けています。

さらに、慢性腎臓病の有病率の上昇、高齢化人口の増加、カルシウム欠乏症の減少、臨床試験数の増加が、二次性副甲状腺機能亢進症治療市場規模を押し上げています。二次性副甲状腺機能亢進症治療のアプローチを用いた疾患治療のための研究活動の増加、確立されたバイオ医薬品および製薬会社の存在は、北米地域の需要促進要因の一部です。OPKO HEALTH, INC.、Amgen Inc.などの重要な競合企業が市場で活発に活動しています。

ダイナミクス

高齢者人口の増加が二次性副甲状腺機能亢進症治療市場の成長を牽引

高齢者人口の増加が二次性副甲状腺機能亢進症治療市場の需要を牽引すると予想されます。この成長は、二次性副甲状腺機能亢進症（SHPT）に続く慢性腎臓病の有病率の上昇によるものです。例えば、世界保健機関（WHO）の2022年報告書によると、2030年までに世界の6人に1人が60歳以上になるとされています。この時点で、60歳以上の人口は2020年の10億人から14億人に増加します。

さらに2050年には、世界の60歳以上の人口は倍増する（21億人）。2020年から2050年の間に、80歳以上の人口は3倍に増え、4,260億人に達すると予想されています。さらに、ビタミンD欠乏症は、二次性副甲状腺機能亢進症を引き起こす老人患者によく見られます。老年人口が増加するにつれ、効果的な治療法に対する需要が起こる可能性が高いです。このように、上記の要因から、予測期間中、市場は拡大すると予想されます。

ビタミンD欠乏症の増加が二次性副甲状腺機能亢進症治療市場の成長を促進する

二次性副甲状腺機能亢進症は、急激な骨代謝の変化、骨量減少、骨形成不全、股関節やその他の骨折によって特徴づけられます。ビタミンD欠乏症は、高齢者、特に家に閉じこもりがちな人や持病のある人の間で蔓延しています。

例えば、クリーブランド・クリニック機構2022年の記事によると、ビタミンD欠乏症は世界の大きな懸念事項です。世界中で約10億人がビタミンD欠乏症であり、50％がビタミンD不足です。二次性副甲状腺機能亢進症のリスクを減らすためには、ビタミンD不足を避けるか、ビタミンDの補充で対処すべきです。したがって、上記の要因により、予測期間中、同市場は優位を占めると予想されます。

二次性副甲状腺機能亢進症の治療に伴う高コストが市場の成長を妨げる

二次性副甲状腺機能亢進症（SHPT）の治療に使用される薬剤の高額な費用は、特に医療保険や医療費の負担が限られた地域に住む人々にとって、効果的な治療を受けることを妨げる可能性があります。

例えば、センシパール（シナカルセト）は、原発性副甲状腺機能亢進症や二次性副甲状腺機能亢進症などの治療に用いられる有名なカルシメトリー薬です。センシパールの経口錠剤は30mgの用量で、30錠入りで約859米ドルします。そのため、新薬の普及を阻害し、市場の成長を妨げる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 老年人口の増加
    • ビタミンD欠乏症の増加
  • 抑制要因
    • 二次性副甲状腺機能亢進症の治療に伴う高コスト
  • 機会
    • 個別化医療に対する需要の増加
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 薬剤クラス別

• ビタミンDアナログ
• カルシメティックス
• リン酸結合剤
• その他

第8章 投与経路別

• 経口
• 静脈内
• 皮下

第9章 流通チャネル別

• 病院
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• OPKO HEALTH, INC.
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Amgen Inc.
• Tairui Biotechnology Co., Ltd.
• sanofi SA
• Validus Pharmaceuticals LLC
• AbbVie Inc.
• ONO PHARMACEUTICAL CO., LTD
• Kyowa Kirin Co., Ltd.
• Teva Pharmaceuticals USA, Inc.
• Pharmanovia

第13章 付録

Overview

Global Secondary Hyperparathyroidism Treatment Market reached US$ 4.3 billion in 2022 and is expected to reach US$ 8.5 billion by 2030 growing with a CAGR of 9.2% during the forecast period 2023-2030. The trend such as the shift towards personalized medicine due to its advances in genetics and biomarker research enables in development of targeted therapies is expected to dominate the global secondary hyperparathyroidism treatment market.

The global secondary hyperparathyroidism treatment market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such emergence of new therapies such as calcimimetics.

Furthermore, the rising prevalence of chronic kidney disease, increasing aging population, decreasing calcium deficiency, increasing number of clinical trials are driving up the secondary hyperparathyroidism treatment market size. The growing research activities for treating disease using secondary hyperparathyroidism treatment approach and presence of establish biopharmaceutical and pharmaceutical companies are some of the factors in demand from North American regions. With significant competitors like OPKO HEALTH, INC., Amgen Inc., and others actively operating in the market.

Dynamics

The Increasing Number of Geriatric Population to Drive the Growth of the Secondary Hyperparathyroidism Treatment Market

The growing number of elderly population is expected to drive the demand for secondary hyperparathyroidism treatment market. This growth is due to elevated prevalence of chronic kidney disease resulting in subsequent secondary hyperparathyroidism (SHPT) growth. For instance, according to World Health Organization 2022 report, 1 out of 6 people in the world will be aged 60 years or over by 2030. At this point, the population aged 60 and up will climb from 1 billion in 2020 to 1.4 billion.

Moreover by 2050, the world's population of persons aged 60 and up will have doubled (2.1 billion). Between 2020 and 2050, the number of people aged 80 and more is expected to treble, reaching 426 Billion. Furthermore, vitamin D deficiency is commonly seen in geriatric patients that results in secondary hyperparathyroidism. As geriatric population increases the demand for effective treatments is likely to happen. Thus, owing to the above factors the market is expected to drive over the forecast period.

The Increasing Number of Vitamin D Deficiency will Drive the Secondary Hyperparathyroidism Treatment Market Growth

The secondary hyperparathyroidism treatment market is expected to drive owing to the lack of vitamin D. The condition is distinguished by rapid bone turnover, bone loss, mineralization defects, and hip and other fractures. Vitamin D deficiency is prevalent among the elderly, particularly in those who are housebound or have a medical condition.

For instance, according to the Cleveland Clinic Organization 2022 article, Vitamin D deficiency is a major global concern. Around 1 billion people worldwide are vitamin D deficient, whereas 50% are vitamin D insufficient. Vitamin D insufficiency affects approximately 35% of adults in the U.S. To reduce the risk of secondary hyperparathyroidism, vitamin D insufficiency should be avoided or addressed with vitamin D supplementation. Thus, owing to the above factors the market is expected to dominate the market over the forecast period.

The High Cost Associated with the Secondary Hyperparathyroidism Treatment Will Hamper the Growth of the Market

The high expense of medications used to treat secondary hyperparathyroidism (SHPT) may stop individuals from obtaining effective treatment, particularly those who live in regions with limited healthcare coverage or affordability.

For instance, sensipar (cinacalcet) is a well-known calcimimetic medication used to treat illnesses such as primary hyperparathyroidism, and secondary hyperparathyroidism. Sensipar's oral tablet at the 30 mg dosage costs about $859 for a 30-tablet supply. Therefore, this high cost associated with the drug may impede the widespread use of new medicines and thereby hampering the market growth.

Segment Analysis

The global secondary hyperparathyroidism treatment market is segmented based on drug class, route of administration, distribution channel and region.

Owing to the Better Effectiveness, the Vitamin D Analogs Segment Accounted for Approximately 49.5% of the Secondary Hyperparathyroidism Treatment Market Share

The vitamin D analogs segment is poised to dominate the secondary hyperparathyroidism treatment market due to its better clinical efficacy in managing the secondary hyperparathyroidism, broader clinical applications, and availability of formulations available in the market. Vitamin D analogs are a type of drug used to treat secondary hyperparathyroidism, a condition in which the parathyroid glands develop excessive amounts of parathyroid hormone (PTH) due to low calcium and vitamin D levels in the blood.

These analogs are intended to decrease PTH gene transcription and parathyroid hyperplasia while having lower calcemic activity, making them a safer alternative to calcitriol. Vitamin D analogs have been shown to improve patient survival in chronic kidney disease (CKD) and correct PTH levels in stage 3 and 4 CKD, potentially preventing renal bone damage and extending patient survival.

Furthermore, vitamin D analogs currently in use include calcifediol, paricalcitol, and doxercalciferol. Newer analogs with higher selectivity are also being developed. Overall, because of their effectiveness and safety in comparison to alternative treatments, vitamin D analogs are positioned to dominate the global secondary hyperparathyroidism market. Thus, due to better efficacy and effectiveness the segment is expected to dominate over the forecast period.

Geographical Penetration

North America Accounted for Approximately 39.1% of the Market Share in 2022, Owing to the Rising Prevalence of Chronic Kidney Disease

North America, particularly the U.S., dominates the global secondary hyperparathyroidism treatment market due to presence of huge number of key players settled in the region, growing prevalence of chronic kidney disease, and high research activities along with increasing clinical trial by major organization in the region. The high prevalence of CKD driving the demand for market in this region owing to the factors such as escalating aging population, sedentary lifestyle, a high prevalence of diabetes and hypertension.

For instance, according to Centers for Disease Control and Prevention 2022 report, approximately the prevalence of chronic kidney disease (CKD) in the U.S. is more than 1 in 7 adults-about 35.5 Billion people, or 14%. Furthermore, CKD is more common in people aging above 65 years and women are more prevalent in compae to men for CKD. Thus, owing to above factors the region is expected to grow over the forecast period.

Competitive Landscape

The major global players in the secondary hyperparathyroidism treatment market include: OPKO HEALTH, INC., Amgen Inc., Tairui Biotechnology Co., Ltd., sanofi SA, Validus Pharmaceuticals LLC, AbbVie Inc., ONO PHARMACEUTICAL CO., LTD, Kyowa Kirin Co., Ltd., Teva Pharmaceuticals USA, Inc., Pharmanovia, and among others.

COVID-19 Impact Analysis

COVID-19 may affect parathyroid gland functioning in two ways which are directly by invasion and indirectly via vitamin D insufficiency and secondary hyperparathyroidism. COVID-19 can be considered a direct cause of hypoparathyroidism. When combined with secondary hyperparathyroidism, vitamin D deficiency may have an adverse effect on the clinical outcome of COVID-19. COVID-19 has had an impact on the care of patients with hypoparathyroidism and hyperparathyroidism.

However, studies suggest that there is no direct evidence that having primary hyperparathyroidism makes the individual more prone to get COVID-19 than anyone else. As a result, the link between COVID-19 and secondary hyperparathyroidism is that COVID-19 might indirectly affect parathyroid gland function via vitamin D insufficiency and secondary hyperparathyroidism, which may have a negative effect on COVID-19's clinical outcome.

By Drug Class

• Vitamin D Analogs
• Calcimimetics
• Phosphate Binders
• Others

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On October 5, 2020, Dr. Reddy's Laboratories Ltd. and its subsidiaries announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets that has been approved by the U.S. Food and Drug Administration (USFDA).

DMI Opinion

The global secondary hyperparathyroidism treatment market is expected to increase due to rising personalized medicine trends fueled by genetic and biomarker advances. Market growth is fueled by factors such as the emergence of drugs such as calcimimetics, growing chronic kidney disease prevalence, an aging population, declining calcium levels, and expanded clinical trials. North America, with its large elderly population and research, plays an important role. OPKO HEALTH, INC., Amgen Inc., Sanofi SA are among the key companies.

However, significant treatment prices, such as Sensipar's $859 for 30 tablets, pose complications. The dominance of the Vitamin D Analogs segment is expected to be driven by efficacy and the prevalence of chronic kidney disease in North America. COVID-19 has an effect on parathyroid function, both directly and indirectly through vitamin D deficiency and secondary hyperparathyroidism.

Why Purchase the Report?

• To visualize the global secondary hyperparathyroidism treatment market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of secondary hyperparathyroidism treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global secondary hyperparathyroidism treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Number of Geriatric Population
    • 4.1.1.2. The Increasing Number of Vitamin D Deficiency
  • 4.1.2. Restraints
    • 4.1.2.1. The High Cost Associated with the Secondary Hyperparathyroidism Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Demand for Personalized Medicine
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. Vitamin D Analogs*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Calcimimetics
• 7.4. Phosphate Binders
• 7.5. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Intravenous
• 8.4. Subcutaneous

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. OPKO HEALTH, INC.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Amgen Inc.
• 12.3. Tairui Biotechnology Co., Ltd.
• 12.4. sanofi SA
• 12.5. Validus Pharmaceuticals LLC
• 12.6. AbbVie Inc.
• 12.7. ONO PHARMACEUTICAL CO., LTD
• 12.8. Kyowa Kirin Co., Ltd.
• 12.9. Teva Pharmaceuticals USA, Inc.
• 12.10. Pharmanovia

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us